Physician profile
Keya Thakkar
NPI 1437682861
$1,903.02
in general payments reported to CMS, 2019-2025
20 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $234 · 2024: $938 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $391.15 | 2023-2025 | Synthroid, Lupron Depot |
| Sanofi-Aventis U.S. LLC | $308.24 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $241.96 | 2023-2025 | Skytrofa |
| Insulet Corporation | $149.56 | 2025 | Omnipod |
| Neurocrine Biosciences, INC. | $128.46 | 2024-2025 | |
| Novo Nordisk INC | $78.87 | 2024 | Sogroya |
| Abbott Laboratories | $70.00 | 2024-2025 | Freestyle Libre |
| Tandem Diabetes Care, INC. | $66.89 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $56.56 | 2024-2025 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $56.35 | 2025 | |
| Endo USA, INC. | $53.19 | 2024-2025 | Supprelin |
| Tolmar, INC. | $49.77 | 2024-2025 | Fensolvi |
| Xeris Pharmaceuticals, INC. | $46.80 | 2023-2024 | Gvoke Hypopen |
| Pfizer INC. | $46.79 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $33.82 | 2023-2024 | Triptodur, Triptodur |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $33.08 | 2025 | Dupixent |
| Genzyme Corporation | $25.82 | 2023 | |
| Ascensia Diabetes Care US INC. | $22.75 | 2024 | |
| Biomarin Pharmaceutical INC. | $22.54 | 2024 | Voxzogo 1.2mg |
| Amneal Pharmaceuticals LLC | $20.42 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keya Thakkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.